目的:基于网络药理学探讨双心方治疗心肌梗死后抑郁的作用机制。方法:通过中药系统药理学数据库及分析平台(traditional Chinese medicine systems pharmacology database and analysis platform, TCMSP)获取双心方活性成分及其对应靶点...目的:基于网络药理学探讨双心方治疗心肌梗死后抑郁的作用机制。方法:通过中药系统药理学数据库及分析平台(traditional Chinese medicine systems pharmacology database and analysis platform, TCMSP)获取双心方活性成分及其对应靶点,GeneCards、PharmGKB数据库搜集心肌梗死与抑郁的相关靶点并整合,将药物靶点与疾病靶点取交集后得到双心方的潜在作用靶点。使用Cytoscape 3.8.2软件构建药物—成分—潜在作用靶点网络,利用STRING数据库进行蛋白质相互作用(protein-protein interaction, PPI)网络分析,并利用DAVID V6.8数据库进行基因本体论(gene ontology, GO)和京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes, KEGG)富集分析。结果:获得双心方的有效成分88个,潜在作用靶点89个,核心靶点10个。通过GO和KEGG富集分析分别获得229条生物学过程条目和34条信号通路。通过HIF-1、PI3K/Akt等多条信号通路介导,双心方中的多重活性成分有心脏保护作用,可通过抗心肌细胞凋亡、抗炎、抗氧化应激反应,促进心肌梗死后心脏内的血管生成等治疗心肌梗死及改善预后,通过抑制神经元的氧化应激损伤、减少炎症介导的细胞毒性和神经元死亡等改善抑郁。结论:双心方主要是通过多靶点、多通路来发挥治疗心肌梗死后抑郁的作用,该研究为后续深入开展双心方治疗心肌梗死后抑郁的作用机制研究提供了依据与方向。展开更多
OBJECTIVE:To evaluated the effectiveness and safety of Chinese herbal medicines(CHMs)for coronary heart disease(CHD)complicated with anxiety.METHODS:Randomized controlled clinical trials(RCTs)with parallel-groups were...OBJECTIVE:To evaluated the effectiveness and safety of Chinese herbal medicines(CHMs)for coronary heart disease(CHD)complicated with anxiety.METHODS:Randomized controlled clinical trials(RCTs)with parallel-groups were included after searching through electric-databases from inception to May,2017.Meta-analysis was undertaken with Rev Man 5.3 software.RESULTS:Twenty-three RCTs enrolling 1654 patients were included in this systematic review.The combination therapy(CHMs combined with anxiolytic)appeared to be superior to anxiolytic in terms of reducing the score of Zung Self-rating Anxiety scale(SAS)(mean Difference(MD),-12.25;95%confidence interval(CI),-14.01 to-10.48,eliminating method;MD,-3.92;95%CI,-5.48 to-2.35,tranquilizing method),improving the total effect rate(relative risk(RR),1.26;95%CI,1.08 to 1.46,eliminating method)and reducing the TCM symptoms scores(MD,-2.24;95%CI,-4.25 to-0.23,tranquilizing method)with a lower incidence of adverse events(RR,0.46;95%CI,0.25 to 0.85,tonifying method).CHMs demonstrated benefits in lowering the score of Hamilton Anxiety Rating scale(MD,-6.77;95%CI,-8.16 to-5.37,tonifying method),lowering the score of SAS(MD,-10.1;95%CI,-13.73 to-6.30,tonifying method)and reducing the TCM symptoms scores(MD,-2.18;95%CI,-3.12 to-1.24,tranquilizing method).CONCLUSION:We got a low evidence that CHMs,which had less side effects,showed potentially benefits to patients with CHD complicated with anxiety.While the results should be interpreted with caution.Trails with higher quality are required to verify the effectiveness and safety of CHMs for CHD complicated with anxiety.展开更多
文摘目的:基于网络药理学探讨双心方治疗心肌梗死后抑郁的作用机制。方法:通过中药系统药理学数据库及分析平台(traditional Chinese medicine systems pharmacology database and analysis platform, TCMSP)获取双心方活性成分及其对应靶点,GeneCards、PharmGKB数据库搜集心肌梗死与抑郁的相关靶点并整合,将药物靶点与疾病靶点取交集后得到双心方的潜在作用靶点。使用Cytoscape 3.8.2软件构建药物—成分—潜在作用靶点网络,利用STRING数据库进行蛋白质相互作用(protein-protein interaction, PPI)网络分析,并利用DAVID V6.8数据库进行基因本体论(gene ontology, GO)和京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes, KEGG)富集分析。结果:获得双心方的有效成分88个,潜在作用靶点89个,核心靶点10个。通过GO和KEGG富集分析分别获得229条生物学过程条目和34条信号通路。通过HIF-1、PI3K/Akt等多条信号通路介导,双心方中的多重活性成分有心脏保护作用,可通过抗心肌细胞凋亡、抗炎、抗氧化应激反应,促进心肌梗死后心脏内的血管生成等治疗心肌梗死及改善预后,通过抑制神经元的氧化应激损伤、减少炎症介导的细胞毒性和神经元死亡等改善抑郁。结论:双心方主要是通过多靶点、多通路来发挥治疗心肌梗死后抑郁的作用,该研究为后续深入开展双心方治疗心肌梗死后抑郁的作用机制研究提供了依据与方向。
文摘OBJECTIVE:To evaluated the effectiveness and safety of Chinese herbal medicines(CHMs)for coronary heart disease(CHD)complicated with anxiety.METHODS:Randomized controlled clinical trials(RCTs)with parallel-groups were included after searching through electric-databases from inception to May,2017.Meta-analysis was undertaken with Rev Man 5.3 software.RESULTS:Twenty-three RCTs enrolling 1654 patients were included in this systematic review.The combination therapy(CHMs combined with anxiolytic)appeared to be superior to anxiolytic in terms of reducing the score of Zung Self-rating Anxiety scale(SAS)(mean Difference(MD),-12.25;95%confidence interval(CI),-14.01 to-10.48,eliminating method;MD,-3.92;95%CI,-5.48 to-2.35,tranquilizing method),improving the total effect rate(relative risk(RR),1.26;95%CI,1.08 to 1.46,eliminating method)and reducing the TCM symptoms scores(MD,-2.24;95%CI,-4.25 to-0.23,tranquilizing method)with a lower incidence of adverse events(RR,0.46;95%CI,0.25 to 0.85,tonifying method).CHMs demonstrated benefits in lowering the score of Hamilton Anxiety Rating scale(MD,-6.77;95%CI,-8.16 to-5.37,tonifying method),lowering the score of SAS(MD,-10.1;95%CI,-13.73 to-6.30,tonifying method)and reducing the TCM symptoms scores(MD,-2.18;95%CI,-3.12 to-1.24,tranquilizing method).CONCLUSION:We got a low evidence that CHMs,which had less side effects,showed potentially benefits to patients with CHD complicated with anxiety.While the results should be interpreted with caution.Trails with higher quality are required to verify the effectiveness and safety of CHMs for CHD complicated with anxiety.